| No. |
DrugBank |
Drug (Description in trials)
[Number of descriptions] |
KEGG DRUG * | KEGG GENES *
[Number of genes] |
KEGG PATHWAY
[Number of pathways] |
Disease ID *
[Number of diseases] |
| 1 | Alemtuzumab | [18] Alemtuzumab; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alemtuzumab (campath ); Alemtuzumab (campath); Alemtuzumab (gz402673); Alemtuzumab 0.2 mg; Alemtuzumab 0.3 mg; Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab and rituximab; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alemtuzumab, rituximab; Filgrastim, alemtuzumab; Transplant conditioning with mobilization and alemtuzumab; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D02802 |
- |
- |
[17] 13, 15, 19, 20, 46, 49, 51, 60, 63, 65, 85, 96, 164, 234, 284, 285, 326 |
| 2 | Anakinra | [8] Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate; | D02934 |
[2] IL1R1, IL1R2 |
[15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| 3 | Arimoclomol | [1] Arimoclomol; | D11374 |
- |
- |
[3] 2, 15, 19 |
| 4 | Bimagrumab | [3] Bimagrumab; Bym338 (bimagrumab); Bym338/bimagrumab; | D10620 |
[2] ACVR2A, ACVR2B |
[4] Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway |
[1] 15 |
| 5 | Botulinum toxin type A | [3] Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a; | D00783 |
[1] SNAP25 |
[2] Insulin secretion, Synaptic vesicle cycle |
[13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
| 6 | Etanercept | [39] 50 mg etanercept; Adalimumab, etanercept, golimumab or infliximab; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Enbrel (etanercept); Etanercept; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (enbrel); Etanercept (enbreltm); Etanercept (full-dose); Etanercept (half-dose); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50 mg solution for injection; Etanercept 50mg; Etanercept biosimilar; Etanercept liquid; Etanercept or adalimumab; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, methotrexate, prednisolone; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tapering or discontinuation of etanercept; Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | D00742 |
[2] LTA, TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
| 7 | Natalizumab | [12] Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg0002 (natalizumab); Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab treatment; Tysabri ® (natalizumab); Tysabri® (natalizumab); | D06886 |
[1] ITGA4 |
[14] Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
[6] 13, 15, 25, 46, 63, 96 |
| 8 | Pioglitazone | [6] Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | D00945
D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
| 9 | Simvastatin | [11] Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Simvastatin; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg film-coated tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; | D00434 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 10 | Sirolimus | [14] Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine; Sirolimus oral liquid product 1mg/ml; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Topical 0.1% sirolimus; | D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |